Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamethasone dipropionate + salicylic acid is a topical combination medication used to treat dry, scaly skin conditions such as psoriasis and eczema. Betamethasone dipropionate is a potent synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressive agent by reducing swelling, redness, and itching in the skin. Salicylic acid is a keratolytic agent (a type of salicylate) that softens and removes the outer layer of scales on the skin by increasing moisture content and dissolving intercellular "cement," thereby enhancing penetration of betamethasone to deeper layers. This combination provides both anti-inflammatory effects from the corticosteroid and enhanced descaling/penetration from the keratolytic action[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate + salicylic acid.